Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Diabetic Peripheral Neuropathic Pain

Diabetic Peripheral Neuropathic Pain Clinical Trial

Official title:

Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Diabetic Peripheral Neuropathic Pain

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04476108
• Other study ID #: 17535
• Secondary ID: H0P-MC-NP01
• Status: Completed
• Phase: Phase 2
• Start date: July 15, 2020
• Est. completion date: November 11, 2021

Study information

• Verified date: November 2023
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is being done to test the safety and efficacy of the study drug LY3016859 for the treatment of diabetic peripheral neuropathic pain. This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 125
• Est. completion date: November 11, 2021
• Est. primary completion date: July 8, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Have a visual analog scale (VAS) pain value =40 and <95 during screening.
• Have a history of daily pain for at least 12 weeks based on participant report or medical history.
• Have a value of =30 on the pain catastrophizing scale.
• Have a body mass index <40 kilograms per meter squared (kg/m²) (inclusive).
• Are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain-relieving therapies (for example, physical therapy) and will not start any new nonpharmacologic pain-relieving therapies during study participation.
• Are willing to discontinue all medications taken for chronic pain conditions for the duration of the study.
• Have daily symmetrical foot pain secondary to peripheral neuropathy present for at least 6 months and as diagnosed through use of the Michigan Neuropathy Screening Instrument Part B =3 (©University of Michigan).
• Have a history and current diagnosis of type 1 or type 2 diabetes mellitus.
• Have stable glycemic control as indicated by a glycated hemoglobin =11 at time of screening.
• Are men, or women able to abide by reproductive and contraceptive requirements.

Exclusion Criteria:

• Have second- or third-degree atrioventricular (AV) heart block or AV dissociation or history of ventricular tachycardia.
• Have had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest (for example, ablation techniques).
• Have surgery planned during the study for any reason, related or not to the disease state under evaluation.
• Have, in the judgment of the investigator, an acute, serious, or unstable medical condition or a history or presence of any other medical illness that would preclude study participation.
• There is an inability to rule out other causative or confounding sources of pain in the primary condition under study.
• Have had cancer within 2 years of baseline, except for cutaneous basal cell or squamous cell carcinoma resolved by excision.
• Have a substance use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (5th edition; DSM-5; American Psychiatric Association).
• Have congenital QT prolongation or QT interval corrected for heart rate using Fridericia's formula (QTcF) interval measurement >450 milliseconds (msec) for male participants, >470 msec for female participants, or >480 msec for participants with bundle branch block.
• Have any clinically important abnormality at screening, as determined by investigator, in physical or neurological examination, vital signs, electrocardiogram (ECG), or clinical laboratory test results that could be detrimental to the participant or could compromise the study.
• Have a positive human immunodeficiency virus (HIV) test result at screening.
• Are, in the judgment of the investigator, actively suicidal and therefore deemed to be at significant risk for suicide.
• Have an intolerance to acetaminophen or paracetamol or any of its excipients.
• Have a history of alcohol, illicit drug, analgesic or narcotic use disorder within 2 years prior to screening.
• Have a current drug-induced neuropathy, for example, due to some types of chemotherapy, or other types of peripheral neuropathy.
• Have known hereditary motor, sensory or autonomic neuropathies.
• Have an estimated glomerular filtration rate (eGFR) of less than 70 milliliters/minute/1.73m² during screening.
• Have any clinically serious or unstable cardiovascular, musculoskeletal disorder, gastrointestinal, endocrinologic, hematologic, hepatic, metabolic, urologic, pulmonary, dermatologic, immunologic, or ophthalmologic disease within 3 months of baseline.
• Have megaloblastic anemia or combined degeneration of the spinal cord.
• Have received any antibodies against nerve growth factor (NGF), or antibodies against EGFR, or EGFR tyrosine kinase inhibitors.
• Have a history of allergic reactions to monoclonal antibodies, or clinically significant multiple or severe drug allergies, including but not limited to erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, or exfoliative dermatitis.
• Have a history or presence of uncontrolled asthma, eczema, significant atopy, significant hereditary angio-edema or common variable immune deficiency.
• Have fibromyalgia

Related Conditions & MeSH terms

• Diabetic Neuropathies
• Diabetic Peripheral Neuropathic Pain
• Neuralgia

Intervention

Drug:
• LY3016859
Administered IV
• Placebo
Administered IV

Locations

Country	Name	City	State
Puerto Rico	Latin Clinical Trial Center	San Juan
United States	VIN-Julie Schwartzbard	Aventura	Florida
United States	Great Lakes Research Group, Inc.	Bay City	Michigan
United States	Northwest Clinical Research Center	Bellevue	Washington
United States	Simon Williamson Clinic	Birmingham	Alabama
United States	Boston Clinical Trials	Boston	Massachusetts
United States	Synexus - US	Chandler	Arizona
United States	Northwestern University	Chicago	Illinois
United States	Synexus Clinical Research	Chicago	Illinois
United States	Synexus - Cincinnati	Cincinnati	Ohio
United States	Rapid Medical Research	Cleveland	Ohio
United States	Aventiv Research Inc	Columbus	Ohio
United States	Clinical Research of South Florida	Coral Gables	Florida
United States	Synexus - US	Dallas	Texas
United States	Altoona Center For Clinical Research	Duncansville	Pennsylvania
United States	Synexus Clinical Research - Glendale	Glendale	Arizona
United States	PharmQuest	Greensboro	North Carolina
United States	Irvine Clinical Research Center	Irvine	California
United States	ActivMed Practices and Research	Methuen	Massachusetts
United States	Suncoast Research Group	Miami	Florida
United States	Synexus - US	Murray	Utah
United States	Coastal Carolina Research Center	North Charleston	South Carolina
United States	Renstar Medical Research	Ocala	Florida
United States	Synexus - US	Omaha	Nebraska
United States	Synexus - US	Orlando	Florida
United States	Synexus - US	Pinellas Park	Florida
United States	Martin E. Hale M.D., P.A.	Plantation	Florida
United States	Rainier Clinical Research Center	Renton	Washington
United States	Artemis Institute for Clinical Research	Riverside	California
United States	StudyMetrix Research	Saint Peters	Missouri
United States	Synexus - US	San Antonio	Texas
United States	Artemis Institute for Clinical Research	San Diego	California
United States	Synexus Clinical Research US, Inc - Orlando	The Villages	Florida
United States	Cotton O'Neil Infusion Center	Topeka	Kansas
United States	MedVadis Research Corporation	Waltham	Massachusetts
United States	Clinical Research Center of Reading,LLC	Wyomissing	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Eli Lilly and Company

Countries where clinical trial is conducted

United States,  Puerto Rico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Average Pain Intensity as Measured by the NRS	The NRS was used during the preliminary data entry period and daily throughout the study to describe pain severity. Participants were asked to describe their average pain over the past 24 hours, on a scale of 0 to 10: 0 = no pain, and 10 = pain as bad as you can imagine.; Posterior mean change from baseline, 95% credible interval (CrI) was derived using Bayesian mixed model repeated measures.	Baseline, up to Week 8
Secondary	Change From Baseline in the Brief Pain Inventory-Short Form (BPI-SF) Total Interference Score	The BPI-SF is a numeric rating scale that assesses the severity of pain (severity scale), its impact on daily functioning (Interference scale), and other aspects of pain (for example, location of pain, relief from medications) in various disease states. BPI-SF score ranges from 0 = no pain to 10 = pain as bad as you can imagine.; Posterior mean change from baseline, 95% CrI was derived using Bayesian mixed model repeated measures.	Baseline, up to Week 8
Secondary	Change From Baseline for Overall Improvement as Measured by Patient's Global Impression of Change	Patients Global Impression of Change captured the participant's perspective of treatment apart from sub-aspects of the general improvement. This is a numeric scale from 1 to 7: 1 = very much better, and 7 = very much worse.; Posterior mean change from baseline, 95% CrI was derived using Bayesian mixed model repeated measures.	Baseline, up to Week 8
Secondary	Change From Baseline for Worst Pain Intensity as Measured by NRS	The NRS was used during the preliminary data entry period and daily throughout the study to describe pain severity. Participants were asked to describe their worst pain over the past 24 hours, on a scale of 0 to 10: 0 = no pain, and 10 = pain as bad as you can imagine.; Posterior mean change from baseline, 95% CrI was derived using Bayesian mixed model repeated measures.	Baseline, up to Week 8
Secondary	Change From Baseline on the Visual Analog Scale (VAS) for Pain	VAS was a graphic, single-item scale where participants were asked to describe their pain intensity over the past week, on a scale of 0 to 100: 0 = no pain, and 100 = worst imaginable pain. Participants completed the VAS by placing a line perpendicular to the VAS line at a point that described their pain intensity.; Posterior mean change from baseline, 95% CrI was derived using Bayesian mixed model repeated measures.	Baseline, up to Week 8
Secondary	Change From Baseline Assessment to Endpoint on the Sleep Scale From the Medical Outcomes Study (MOS Sleep Scale)	The MOS Sleep Scale consists of 12 questions addressing the past week. Participants reported how often each sleep symptom or problem was present on a 5-point categorical scale ranging from 'all of the time' to 'none of the time.' It includes 12 questions with the first question assessing how long it takes the subject to fall asleep. The second question asks how many hours each night the subject slept. The remaining 10 questions have a range of 6 responses from 1="all of the time" to 6="none of the time". MOS Sleep scale scores range from 0 (min) to 100 (max). The original survey items are converted to a 0 to 100 range (by Converting 1 to 0, 2 to 25, 3 to 50, 4 to 75, and 5 to 100). Higher scores represent worse outcomes.; Posterior mean change from baseline, 95% CrI was derived using Bayesian longitudinal model.	Baseline, up to Week 8
Secondary	Total Amount of Rescue Medication Use as Measured by Average Dosage Per Week	Total Amount of Rescue Medication Use as Measured by Average Dosage per Week. Posterior mean change from baseline, 95% CrI was derived using Bayesian mixed model repeated measures.	Baseline up to Week 8
Secondary	Change From Baseline on the EuroQol-5D 5 Level Questionnaire (EQ-5D-5L) (United States)	The EQ-5D-5L assessed quality of life based on 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant was asked to 'check the ONE box that best describes your health TODAY,' choosing from 5 options (no problems, slight problems, moderate problems, severe problems, extreme problems) provided under each dimension. The scores in the 5 dimensions were summarized into a health state index score. The health state index value is a single value on a scale from less than 0 to 1 (negative values are valued as worse than death) with higher scores indicating better health: 0 = a health state equivalent to death, and 1 = perfect health.; Posterior mean change from baseline, 95% CrI was derived using Bayesian mixed model repeated measures.	Baseline, up to Week 8

External Links

•   A Study of LY3016859 in Participants With Diabetic Peripheral Neuropathic Pain